Home

James Huang

CIK 1573160 · Chief Executive Officer · last filed 2026-06-02

James Huang is a Chief Executive Officer who has filed 44 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing shows the insider bought $371.6K of CNTB on Jun 2, 2026. Across all open-market trades the lifetime net is +$8.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $30.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$30.09M

Companies

7

Total Filings

44

Lifetime Open-Market Net

$8.60M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CNTB Director 13,310,000 $2.08 $27.68M $4.37M 2 2026-06-02
ATRA Director 307,894 $7.81 $2.40M -$4.99M 3 2026-05-11
TCRT Director 1,256 $1.90 $2.4K $0 3 2023-06-08
WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted Director 84 $0.01 $1 $7.73M 17 2023-02-23
CASI Pharmaceuticals, Inc. (CASI) Delisted Director 371,708 $0.28 $104.1K $1.32M 14 2022-09-08
Alaunos Therapeutics, Inc. (ZIOP) Delisted Director 108,333 $0.87 $93.8K $171.0K 3 2021-09-03
CASI Pharmaceuticals, Inc. (ENMD) Delisted Director — — — $0 1 2013-05-31

Recent Filings

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-02 CNTB Buy (P) +150,000 $371.6K EDGAR
2026-05-11 ATRA Sell (S) −626,892 -$6.33M EDGAR
2026-04-01 CNTB Buy (P) +1,160,000 $4.00M EDGAR
2025-12-01 ATRA Mixed +97,472 -$18 EDGAR
2025-08-19 ATRA Buy (P) +110,000 $1.34M EDGAR
2023-06-08 TCRT Grant (A) — $0 EDGAR
2023-05-18 — Disp (D) — $0
2023-02-23 WINDTREE THERAPEUTICS INC /DE/ (WINT) Delisted Mixed +1,112,308 $156.9K EDGAR
2022-09-08 CASI Pharmaceuticals, Inc. (CASI) Delisted Buy (P) +55,573 $229.7K EDGAR
2022-09-02 CASI Pharmaceuticals, Inc. (CASI) Delisted Buy (P) +37,196 $139.0K EDGAR
Showing 1–10 of 44
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.